Skip to main content
. 2022 Jan 11;8:804396. doi: 10.3389/fmolb.2021.804396

FIGURE 3.

FIGURE 3

Schematic diagram of the HMGB1-siRNA@SNALP-pPB nanoparticle targeting HSCs to silence HMGB1 to show antifibrotic and anti-inflammatory effects for hepatic cirrhosis (Zhang et al., 2020).